While the "Fast Money" traders are always fast, they're not always right.
Take Guy Adami of Drakon Capital, for example, who on Sept. 7 recommended Human Genome . Since then, the stock has fell by 16 percent. The biotech space has hit some bumps, but Adami is sticking with his call on a long-term basis because he thinks it will go higher.
Watch the video to see his full explaination.